Get the Stockscreener App
6.22
0.00%
0.00
Silo Pharma Inc stock is traded at $6.22, with a volume of 14,269.
It is up +0.00% in the last 24 hours and up +6.05% over the past month.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.
See More
Previous Close:
$6.22
Open:
$6.28
24h Volume:
14,269
Relative Volume:
0.05
Market Cap:
$6.52M
Revenue:
$72,100
Net Income/Loss:
$-4.84M
P/E Ratio:
-0.8342
EPS:
-7.4566
Net Cash Flow:
$-3.84M
1W Performance:
+1.63%
1M Performance:
+6.05%
6M Performance:
+7.62%
1Y Performance:
-35.51%
1-Day Range:
$5.80
$6.28
1-Week Range:
$5.80
$6.4114
52-Week Range:
$3.315
$15.15
Silo Pharma Inc Stock (SILO) Company Profile
Name
Silo Pharma Inc
Sector
Industry
Phone
(718) 400-9031
Address
677 N. WASHINGTON BLVD, SARASOTA
Compare SILO vs MOBBW, SHMD, GOODO, PSNYW, DWLD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SILO
SILO PHARMA INC
|
1.71 | 17.96M | 0 | 0 | 0 | 0.00 |
MOBBW
Mobilicom Limited Warrants
|
1.84 | 2.93B | 0 | 0 | 0 | 0.00 |
SHMD
Schmid Group N V
|
5.85 | 379.52M | 52.15M | -21.46M | 0 | -0.4675 |
GOODO
Gladstone Commercial Corporation
|
19.89 | 372.90M | 0 | 0 | 0 | 0.00 |
PSNYW
Polestar Automotive Holding Uk
|
2.5075 | 212.76M | 2.07B | -1.42B | -1.37B | -0.6765 |
DWLD
Davis Select Worldwide ETF
|
45.75 | 0 | 0 | 0 | 0 | 0.00 |
Silo Pharma Inc Stock (SILO) Latest News
Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial - Sahm
Silo Pharma reports positive stability data for stress treatment SPC-15 - TipRanks
Silo Pharma reports stability data for intranasal drug SPC-15 By Investing.com - Investing.com Canada
Silo Pharma Says SPC-15 PTSD Nasal Spray Remains Stable for 9 Months - marketscreener.com
Silo Pharma Reports Positive Stability Data for SPC-15 PTSD - GlobeNewswire
Silo Pharma Regains Nasdaq Compliance, Stabilizing Listing Status - The Globe and Mail
Silo Pharma regains compliance with Nasdaq min bid price requirement - TipRanks
Silo Pharma Regains Nasdaq Compliance and Advances PTSD Drug SPC-15 Toward Clinical Trials - Minichart
SILO News | SILO PHARMA INC (NASDAQ:SILO) - ChartMill
Silo Pharma regains Nasdaq minimum bid price compliance, ticker SILO - TradingView
Silo Pharma (SILO) restores Nasdaq minimum bid price compliance status - Stock Titan
Silo Pharma (SILO) to vote on director slate, auditor and stock increase at Aug 14 meeting - Stock Titan
Silo Pharma Says it Regained Compliance With Nasdaq's Minimum Bid Price Requirement - marketscreener.com
Silo Pharma Regains Nasdaq Compliance - Intellectia AI
Silo Pharma Regains Compliance With Nasdaq Minimum Bid Price Requirement - TradingView
Silo Pharma regains Nasdaq minimum bid price compliance By Investing.com - Investing.com India
Silo Pharma clears Nasdaq’s bid-price test; stock stays listed - Stock Titan
SILO Stock Price, Quote & Chart - ChartMill
Silo Pharma Inc (SILO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Silo Pharma Inc (SILO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Silo Pharma Inc (SILO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Silo Pharma Inc (SILO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Silo Pharma Inc (SILO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Silo Pharma Inc (SILO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Silo Pharma Inc (SILO) Institutional Confidence - TradingKey
Silo Pharma Inc (SILO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Silo Pharma Inc (SILO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
SILO PHARMA INC (SILO) Stock Chart - ChartMill
SILO Q4 2023 Earnings: EPS Misses Estimates; Pre-Revenue Biotech Faces Cash Burn ConcernsEarnings Outlook Update - newsline.com
SILO Q4 2023 Earnings: EPS Misses Estimates as Company Advances PipelineDividend Cut Risk - newsline.com
Why Did SILO Stock Soar 85% Today? - Stocktwits
Silo Pharma Implements Reverse Stock Split and Restructures Capital - The Globe and Mail
Silo Pharma Shares Drop Following Implementation of 1-for-15 Reverse Stock Split - Moomoo
Silo Pharma (SILO) completes 1-for-15 reverse stock split and cuts authorized shares - Stock Titan
Silo Pharma Announces 1-for-15 Reverse Stock Split - The Globe and Mail
Silo Pharma announces 1-for-15 reverse stock split effective June 2 - Investing.com UK
Silo Pharma announces 1-for-15 reverse stock split effective June 2 By Investing.com - Investing.com South Africa
Silo Pharma to implement 1-for-15 reverse stock split, issued shares fall to ~1.084M - TradingView
Reverse split shrinks Silo Pharma (NASDAQ: SILO) share count and authorization - Stock Titan
SILO Q4 2023 Earnings: EPS Misses Estimates as Development-Stage Biotech Maintains FocusWeak Earnings Momentum - The Legal Advocate
Silo Pharma (SILO) Holds Near Support as Biotech Stock Edges HigherDealer Delta - newsline.com
Silo Pharma Inc. (SILO) Holds Above $0.40 Support After Modest GainsSupport Level Bounce - newsline.com
Silo Pharma (SILO) Surges 5% as Small-Cap Biotech Recovers From Recent LowsSupply Zone - newsline.com
Silo Pharma Inc. (SILO) Rallies 3.99% as Biotech Sentiment Improves — Key Levels in FocusDebt Free Companies - The Legal Advocate
Silo Pharma Inc. (SILO) Q4 2023 Earnings: Widening Losses as Pre-Revenue Biotech Focuses on Pipeline ProgressProfit Margin Analysis - Newser
SILO Q4 2023 Earnings: Biotech Misses EPS Estimates as Pre‑Revenue Phase ContinuesCrowd Stock Picks - Newser
Silo Pharma Inc. (SILO) Edges Higher as Shares Test Key ResistanceAggressive Growth Picks - Newser
Silo Pharma (SILO) Q4 2023 Results Disappoint: What Investors Should KnowRevenue Miss Report - The Legal Advocate
Silo Pharma (SILO) Q4 2023 Earnings: Miss Sparks ConcernTrending Entry Points - Newser
Silo Pharma (SILO) Stock Analysis: Falls -3.79%, Watching $0.35 2026-05-19NHNL Ratio - The Legal Advocate
Silo Pharma Inc Stock (SILO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Silo Pharma Inc Stock (SILO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Weisblum Eric | Chief Executive Officer |
Nov 20 '25 |
Buy |
0.37 |
1,000 |
370 |
210,932 |
| Weisblum Eric | Chief Executive Officer |
Nov 21 '25 |
Buy |
0.36 |
1,000 |
365 |
211,932 |
| Weisblum Eric | Chief Executive Officer |
Nov 18 '25 |
Buy |
0.40 |
7,500 |
3,025 |
205,432 |
| Weisblum Eric | Chief Executive Officer |
Nov 19 '25 |
Buy |
0.41 |
4,500 |
1,823 |
209,932 |
0.03%
5.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):